TP53p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient
Open Access
- 9 April 2013
- journal article
- case report
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 13 (1), 187
- https://doi.org/10.1186/1471-2407-13-187
Abstract
Adrenocortical carcinomas (ACCs) are among the most common childhood cancers occurring in infants affected with the Li-Fraumeni and Li- Fraumeni-like (LFS/LFL) syndromes, which are caused by dominant germline mutations in the TP53 gene. In Brazil, a particular mutation, occurring in the tetramerisation domain of the gene, p.R337H, is exceedingly common due to a founder effect and is strongly associated with ACC. In this report, we describe the phenotype and long-term clinical follow-up of a female child diagnosed with ACC and homozygous for the TP53 p.R337H founder mutation. At age 11 months, the patient was diagnosed with a virilising anaplastic adrenal cortical tumour, which was completely excised without disturbing the adrenal capsule. Family history was consistent with an LFL tumour pattern, and genotyping identified the TP53 p.R337H mutation in both alleles in genomic DNA from lymphocytes and fibroblasts. Haplotype analysis confirmed the occurrence of the mutation in the same founder haplotype previously described in other Brazilian patients. No other germline or somatic TP53 mutations or rearrangements were identified. At age 9 years, the child was asymptomatic and had no evidence of endocrine derangements. Full body and brain magnetic resonance imaging (MRI) failed to detect any suspicious proliferative lesions, and cardiopulmonary exercise testing results were within the normal reference for the child’s age, ruling out a major exercise capacity deficiency. This is the first clinical and aerobic functional capacity documentation of a patient who carries two mutant TP53 alleles and no wild-type allele. Our results support the hypothesis that TP53 p.R337H, the most common TP53 mutation ever described in any population, is a conditional mutant. Furthermore, our observations over a long period of clinical follow-up suggest that TP53 p.R337H homozygotes do not have a more severe disease phenotype than do heterozygote carriers of the same mutation. Patients with the homozygous TP53 p.R337H genotype will require careful surveillance for lifetime cancer risk and for effects on metabolic capacity later in life.Keywords
This publication has 32 references indexed in Scilit:
- p53Current Opinion in Oncology, 2012
- CHEK2*1100delC homozygosity is associated with a high breast cancer risk in womenJournal of Medical Genetics, 2011
- Detailed haplotype analysis at theTP53locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effectHuman Mutation, 2009
- p53 Improves Aerobic Exercise Capacity and Augments Skeletal Muscle Mitochondrial DNA ContentCirculation Research, 2009
- Association of the germline TP53R337H mutation with breast cancer in southern BrazilBMC Cancer, 2008
- The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian familiesCancer Letters, 2007
- Prevalence of Early Onset Colorectal Cancer in 397 Patients With Classic Li–Fraumeni SyndromeGastroenterology, 2006
- p53 Unfolding Detected by CD but Not by Tryptophan FluorescenceBiochemical and Biophysical Research Communications, 2001
- Relative frequency and morphology of cancers in carriers of germline TP53 mutationsOncogene, 2001
- An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinomaProceedings of the National Academy of Sciences of the United States of America, 2001